going from tirzepatide to semaglutide vs. Semaglutide: What You Should Know How to Switch from Tirzepatide
Description
Survodutide, a glucagon and GLP-1 receptor co-agonist developed by Boehringer Ingelheim, is currently in clinical trials
doi:10.1016/j.cmet.2018.03.001 11
injections of 100 nmol kg 1 MK-801 ( n = 12 rats), 100 nmol kg 1 GLP-1 ( n = 12 rats), 100 nmol kg 1 GLP-1MK-801 ( n = 12 rats) or vehicle (isotonic saline, n = 13 rats) for three consecutive days while being offered the voluntary choice between chow and kaolin (a non-food product)
MOTS-c targets skeletal muscle and can enhance glucose metabolism
At SMC, we have evaluated both compounds in the STAM mouse model and confirmed improvements in NAS and fibrosis
